Ettatum to: Patient-derived xenografts for individualized care in advanced sarcoma (Cancer, (2014), 120, (2006-2015), 10.1002/cncr.28696);Patient-derived xenografts for individualized care in advanced sarcoma

Cancer

Volumn 120, Issue 13, 2014, Pages 2006-2015

  Stebbing, Justin ^a   Paz, Keren ^b   Schwartz, Gary K ^c   Wexler, Leonard H ^c   Maki, Robert ^d   Pollock, Raphael E ^e   Morris, Ronnie ^b   Cohen, Richard ^f   Shankar, Arjun ^f   Blackman, Glen ^f   Harding, Victoria ^a   Vasquez, David ^b   Krell, Jonathan ^a   Ciznadija, Daniel ^b   Katz, Amanda ^b   Sidransky, David ^g  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Champions Oncology ^*  (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; chemotherapy; mice; prediction; response; sarcoma; trial; TumorGraft

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERIBULIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; P 1446A 05; PACLITAXEL; PAZOPANIB; RUXOLITINIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG; VINCRISTINE; VISMODEGIB; VORINOSTAT;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CANCER PATIENT; CANCER SURGERY; CANCER TRANSPLANTATION; CARDIOTOXICITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; EWING SARCOMA; HUMAN; HUMAN TISSUE; LIPOSARCOMA; MOUSE; MULTIPLE CYCLE TREATMENT; MYXOMA; NONHUMAN; ONCOLOGICAL PROCEDURE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SARCOMA; SYNOVIAL SARCOMA; TREATMENT RESPONSE; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT;

BIOMARKER; CHEMOTHERAPY; MICE; PREDICTION; RESPONSE; SARCOMA; TRIAL; TUMORGRAFT;

AGED; ANIMALS; CHILD; CHONDROSARCOMA; FEMALE; HETEROGRAFTS; HUMANS; INDIVIDUALIZED MEDICINE; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MICE; MICE, SCID; MIDDLE AGED; MYXOMA; RHABDOMYOSARCOMA; SARCOMA; SARCOMA, EWING; SARCOMA, SYNOVIAL; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 84902545660     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28928     Document Type: Erratum

References (26)

1. Nielsen TO, West RB,. Translating gene expression into clinical care: sarcomas as a paradigm. J Clin Oncol. 2010; 28: 1796-1805.
2. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumors: a gene expression study. Lancet. 2002; 359: 1301-1307.
3. Henderson SR, Guiliano D, Presneau N, et al. A molecular map of mesenchymal tumors [serial online]. Genome Biol. 2005; 6: R76.
4. Segal NH, Pavlidis P, Antonescu CR, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol. 2003; 163: 691-700.
5. Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005; 65: 9226-9235.
6. Nilbert M, Meza-Zepeda LA, Francis P, et al. Lessons from genetic profiling in soft tissue sarcomas. Acta Orthop Scand. 2004; 75 (suppl): 35-50.
7. Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003; 9: 1941-1956.
8. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA,. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol. 2007; 8: 513-524.
9. Nielsen TO,. Discovery research to clinical trial: a ten year journey [serial online]. Clin Invest Med. 2010; 33: E342-E348.
10. Hahn WC, Weinberg RA,. Rules for making human tumor cells. N Engl J Med. 2002; 347: 1593-1603.
11. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR,. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell. 2007; 11: 375-388.
12. Davis SR, Meltzer PS,. Modeling synovial sarcoma: timing is everything. Cancer Cell. 2007; 11: 305-307.
13. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10: 515-527.
14. Kao J, Salari K, Bocanegra M, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery [serial online]. PLoS One. 2009; 4: e6146.
15. Gerlinger M, Rowan AJ, Horswell S, et al. Intra-tumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-892.
16. DeRose YS, Wang G, Lin YC, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011; 17: 1514-1520.
17. Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011; 1: 508-523.
18. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2010; 10: 3-8.
19. Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011; 10: 1311-1316.
20. Morelli MP, Calvo E, Ordonez E, et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol. 2012; 30: e45-e48.
21. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009; 324: 217.
22. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-1417.
23. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29: 2011-2019.
24. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486: 537-540.
25. Brower SL, Fensterer JE, Bush JE,. The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. Methods Mol Biol. 2008; 414: 57-78.
26. Junttila MR, de Sauvage FE,. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501: 346-354.